Hims & Hers launches Peptides+ treatments

Hims & Hers launches Peptides+ treatments

CNBC • • business

Key Points:

  • Hims & Hers Health has launched its Peptides+ platform offering five compounded peptide and longevity treatments in the U.S., none of which are FDA-approved but are legally authorized and prepared by licensed pharmacies.
  • The company acknowledges limited scientific data on the efficacy and optimal use of these peptides and plans to tailor treatments through licensed providers with ongoing patient monitoring and dose adjustments as needed.
  • The new offerings follow eased federal restrictions allowing compounding of certain unapproved peptides, which have gained popularity for muscle growth, recovery, and anti-aging despite lacking robust clinical trial evidence.
  • Experts warn of potential risks due to the absence of large-scale human trials, uncertain dosing, and possible immune reactions, emphasizing the need for careful medical supervision, which Hims aims to provide through its telehealth platform.
  • Scientific evidence supporting these peptides varies, with some compounds like NAD+ and glutathione showing little proven benefit, while others like L-carnitine have limited weight loss effects; safety concerns have also been raised regarding compounded glutathione products.

Trending Business

Trending Technology

Trending Health